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                          Abstract 
 This study was conducted for evaluating the efficiency of 
Cymelarsan drug on a Trypanosoma evansi isolate in 
experimentally infected rabbits which had a chronic infection for 
both treatment and protective activity.The experiment was carried 
out in 30 rabbits which were divided into four groups: 
 A group of 12 rabbits were infected with T.evansi isolate and 
treated with Cymelarsan. They were then grouped in pairs and 
each treated with a different dose of Cymelarsan drug.  These 
doses were 5 mg/kg, 2.5 mg/kg, 1.25 mg/kg, 0.625 mg/kg, 
0.312 mg/kg and 0.156 mg/kg respectively. 
Control groups included:  
       6 rabbits were infected with the parasite and left untreated.        
An uninfected control group of 6 rabbits was treated with 
Cymelarsan . 
      An uninfected and untreated group of 6 rabbits was kept as a          
negative control. 
   All the groups were daily examinated for a period of 60 days    
post treatment.  
All treated groups remained alife while the infected died within 30 
days post infection.  
VII 
 
60 days post treatment rabbits were challenged with T.evansi. 
 Blood from the reinfected rabbits was inoculated in mice .This 
revealed that all animals were protected except at a dose of 
0.156mg/kg. 
  This indicates that at the dose of 0,156mg/kg; Cymelarsan 
showed no protection and therefore it was not prophylactic after 60 
days of reinfection as indicated by positive parasitaemia in sub 
inoculated mice.   
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                    CHAPTER ONE 
 1. Introduction:- 
Animal trypanosomosis comprises a group of diseases caused 
by several species of blood and tissue dwelling protozoan 
parasites. 
Trypanosomosis are a group of disease produced by trypanosomes 
in an area that covers much of the tropical and sub tropical regions 
of the world. 
The disease is generally a chronic condition, which is usually 
fatal if not appropriately treated. The disease could be acute, sub-
acute or chronic. It leads to considerable loss of weight and 
anemia. Various symptoms are exhibited including fever, oedema, 
dermatitis and nervous disorders (Finelle,1983).  
         African animal trypanosomosis can be caused by several 
trypanosome species. In camels, the main pathogenic species is T. 
evansi which causes a disease generally referred to as "surra ". 
         Control of animal trypanosomosis is important but difficult 
because of the wide range of animal species that are susceptible to 
the disease and the diversity of trypanosoma species. Control may 
involve initiation and maintenance of tsetse control programs and / 
or chemotherapy and chemoprophylaxis for livestock (Williamson, 
 1979; Ikede,1989). 
1 
         Considerable efforts have been made to control the disease 
 through vector control. Different methods have been tried e.g. bush 
clearance, trapping, application of insecticides and wild animal 
eradication. Development of a vaccine has proved to be difficult at 
present because of the problems of antigenic variation of the 
parasite (Nantulya,1986). 
        At present the use of trypanocidal drugs for treatment or 
prophylaxis of livestock is an important control strategy for 
trypanosomosis. However, no new drugs have been introduced on 
the market for control of trypanosomosis in the last 25 years. 
However , two drugs were under experimental trials: Difluoro 
methylornithine (DFMO) (Bacchi, etal,1980 ) for treatment of sleeping 
sickness and cymelarsan (RM 110) for treatment of camel 
trypanosomosis (Denning etal,1989). The commercially available 
drugs for animal trypanosomosis are at present limited to the 
following compounds: Ethidium, Berenil, Samorin, Suramin and 
Antrycide. However, the extensive use of these compounds led to 
the appearance of drug-resistance which is becoming more and 
wider spread (Leach and Roberts, 1981).    
1-1. Objectives of the study:- 
This study was designed:  
1. To determine the curative dose rates of cymelarsan on T. 
evansi in chronically infected rabbits. 
2. To determine the protective effect of serial doses of 
 cymelarsan used for treating rabbits after challenge with 
T.evansi. 
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 1-2. Literature Review: 
1-2-1. Definition : 
       In Africa, various haematophagous insects, mainly Glossina- 
spp commonly known as tsetse flies transmit the trypanosomes. 
These are considered to be the true vectors of these parasites. 
Tsetse flies occur exclusively in Africa over an area of 
approximately10 million km2 extending on both sides of the 
Equator (Itard ,1981). 
     Tsetse flies are of primary importance in the epidemiology of 
this economically and socially important disease. However, T. 
evansi, though can be transmitted mechanically by tsetse flies, it is 
mainly transmitted mechanically by other blood sucking flies such 
as tabanids and stomoxys and not by tsetse flies. 
 
1-2-2. Transmission of Trypanosomes:- 
 Animal, trypanosomes are either transmitted:-   
      1) Cyclically. 
      2) Mechanically. 
      3) By other means. 
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1-2-2-1.  Cyclical Transmission:-                                              
 Some trypanosomes are transmitted cyclically during which they 
undergo a development process and a multiplication in the vector. 
This occurs in the Glossina Species, which are the vector for T. 
brucei - T. vivax – T. congolense.                                                                                               
 
1-2-2-2.  Mechanical   Transmission:-                                      
     This takes place by biting flies including Tabanids and 
Stomoxys flies. A biting insect passes the blood from the infected 
animal to another in the course of the interrupted feeding. The 
pathogen can only be carried in the fly over a short period of time 
since it will survive only for a short time in the proboscis of the 
tabanide. In contrast the transmission by tsetse flies is a complex 
mechanism in which the tsetse fly remains life long 
carrier.(Horst,1995).It also takes place by a careless operator 
including involuntarily using unhygienic procedures, such as 
contaminated instruments (Uilenberg,1998). Apart from 
transmitting trypanosomes cyclically, Glossina species can also act 
as mechanical vectors (Uilenberg, 1998).                                                                                      
       It is suggested that animals species (Cattles-goats-buffalo) 
may be reservoir of T. evansi and they could carry symptomless 
chronic infection of T. evansi (Mahmoud and Elmalik,1978). 
5 
1-2-2-3. Transmission by other means:- 
        Lions, hyenas, dogs and cats can be infected with T. evansi- T. 
brucei by feeding on the carcasses of infected animals (Brown etal 
1990) as long as these are carcases still sufficiently fresh to contain 
live trypanosomes. 
       Pathak et al, (1999) reported that T. evansi, was transmitted 
congenitally from mother to fetus via placenta or when bleeding 
occurs during birth. 
      Vampire bats are capable of transmitting T. evansi from 
infected to clean animals (Uilenberg,1998). 
      Also venerial transmission is the normal means by which 
dourine of equines, caused by T. equiperdum, is propagated 
(Uilenberg,1998). 
1-2-3. Pathogenesis:- 
       Trypanosomosis, like other infectious diseases, starts with an 
increase of the body temperature, a hyperthermia and petechical 
hemorrhage of serous membranes (Soulsby,1982 and OIE, 2000).This is 
a result of the contact between the trypanosomes multiplying in the 
host and the defence system of the host. Anemia is one of the main 
symptoms of the disease. It is the dominant feature (Luckins, 
1999), which comprises two phases: an acute hemolytic phase 
associated with rising parasitaemia and a chronic phase associated 
with declining parasitaemia. At the early stage of the infection 
there is increase in white blood cells (phagocytes) that engulf any 
 invaders that enter the host. The red blood cells which are coated 
by the remaining material of the lysis of trypanosomes, give a 
wrong signal to phagocytes which remove any foreign material, so 
the coated red cells are destroyed. The other guess is that 
trypanosomes release toxic substances which destroy the red cells 
directly by lysis (Uilenberg, 1998). The surface protein of 
trypanosome inhances the defense system to produce specific 
antibodies; hence almost most trypanosomes are destroyed, but 
still some mutate and continue to 
 Survive and change their surface protein and as a result the old 
specific antibodies do not recognize them. 
This leads to multiplication and increase of new parasitaemia with 
the result that temperature is elevated again. 
In postmortem the carcass is emaciated and dehydrated. The 
disease may be fatal within months or may last for few years.                                 
 
1-2-4. African animal trypanosomosis:- 
      Trypanosomosis are usually a chronic disorder; the duration 
and symptoms of which vary with animal host species and the 
pathogen (Brown et al,1990). 
      Diseases due to typically African Trypanosomes (T.vivax, T. 
congolense, T. brucei, T. suis) are all cyclicaly transmitted by flies. 
This group of diseases is some times generally termed (Nagana), 
 which was used exclusively for Trypanosomosis due to T. brucei.  
Dourine is trypanosomosis of equines due to T. equiperdum 
(Brown et al,1990). 
 
1-2-4-1. Camel Trypanosomosis:- 
       Surra, trypanosomosis of camelidae and equidae due to T. 
evansi, is mainly transmitted by bitting insects other than tsetse 
flies. 
       The most pathogenic species to the camel is T. evansi. It was 
the first trypanosome to be described and identified as cause of 
mammalian trypanosomosis. In the blood stream T. evansi usually 
occurs as monomorphic trypomastigotes 15-36 µm in length with a 
mean of 24 µm. There is small sub–terminal kinetoplast in the cell. 
The morphology is therefore typically that of the slender forms of 
the other members of the sub genus Trypanozoon (Soulsby,1982). 
      Stumpy forms are observed, but rarely. Division is by 
longitudinal binary fission.  
      The earliest reports on the trypanosome were published by 
Griffith Evans in 1880 who associated it with an endemic disease 
in equines and camels known as (surra) in India (Evans,cited by 
INDRAKAMHANG,1998). It is believed to have originated in 
Africa as a result of camels entering the tsetse belt and becoming 
infected with pleomorphic T. brucei and returning to the dry zone 
 where T. evansi developed as monomorphic. In Africa and Asia: 
sheep, goat, deer and antelope are carriers of T. evansi. Although, 
dogs are highly susceptible, the acute course of the disease 
disqualifies these as effective reservoirs.  
 
1-2-4-2. Transmission of T. evansi:-  
     No cyclical transmission of T. evansi occurs and the infection is 
transmitted between hosts mechanically.  
      There is an apparent link between the seasonal occurrence of 
outbreaks of T.evansi in camels in Sudan and that of the great 
abundance of Tabanids during the rainy season. However, tabanid 
species are present throughout the year ensuring that transmission 
continues, albeit to a lesser extent. 
     Most out breaks occurred during the rainy season. There is 
definite correlation between the seasonal outbreaks of T. evansi 
infection and the increase of Tabanids during the tropical rainy 
seasons in the Sudan (Mahmoud&Gray, 1980). 
 
1-2-4-3.  Pathogencity of T. evansi: 
      Surra in camels is manifested by an elevation of body 
temperature which is directly associated with parasitaemia and 
progressive development of anemia, loss of condition and 
weakness. Fever, odema and petechial haemorrhages in serous 
 membranes may be observed. The disease may be fatal within a 
month or may last for few years. Spontaneous recovery is rare 
(Hornby, 1952 and Brown et al, 1990).                         
 
1-2-5. Control of Trypanosomosis:- 
       Since trypanosomosis is a vector-borne disease, this can be 
based on: 
      1- Vector control. 
      2- Trypanotolerance. 
      3- Chemotherapy.  
 
1-2-5-1. Vector control:- 
        Glossina species have been the target for a variety of control 
operations. Various methods have been used to control tsetse, 
indirect and direct methods include hand catching; trapping; bush 
clearance; elimination of wild life; ground spraying with persistent 
insecticides; and aerial spraying with non-persistent insecticides 
and more recently,using odour baited traps (Dransfield etal,1990) and 
insecticide impregnated targets (Opiyo etal, 1990) Trial of “pour–on”, 
application of synthetic pyrethroids to cattle against tsetse in 
Kenya has also given encouraging results (Stevenson etal ,1998) and 
dipping cattle in pyrethroids. All these above methods have little 
effect on tabanids.  
 1-2-5-2.  Trypanotolerance:- 
      In many species of livestock,especially exotic breeds (cattle-
sheep and goats), trypanosomosis causes a severe disease that often 
terminates in death of the animal. In wild bovidae, however the 
disease course is different, these animals have a remarkable degree 
of resistance to clinical trypanosomosis probably as a result of 
natural selection. These animals do get infected but they do not 
develop severe clinical disease. Recent investigations have shown 
that the increased resistance of wild animals to the ill-effects of 
trypanosome infection may be related to their innate ability to 
control the levels of parasitaemia (Murray et al, 1982) certain 
indigenous breeds of cattle in west and central Africa can also 
better tolerate exposure to trypanosomosis (Murray etal, 1982). There 
is also evidence for similar breed in East Africa such as Orma 
Boran (Njogu etal, 1985). 
     These naturally resistant (trypanotolerant) livestock breeds offer 
a potential means for improving agricultural productivity in tsetse 
infested areas of Africa.  
    Trypanotolerance mechanisms were often attributed to 
differences in immune responses. (Murray etal, 1982) within different 
breeds of cattle. 
 
1-2-5-3. Chemotherapy: 
        The use of trypanocides is wide-spread over the world and are 
commonly used for controlling animal trypanosomosis (Leach and 
Roberts, 1981).    
      Chemotherapy and chemoprophylaxis will continue to play an 
important role in the control of trypanosomosis. This approach has 
been widely used with considerable success. Chemotherapy and 
chemoprophylaxis have been practiced in the field as a means of 
trypanosomosis control for many years. Increased drug 
development cost, the generally small drug budgets of developing 
countries and wide spread emergence of drug resistance are 
primary causes. (Williamson, 1970). Such drugs are curative. They 
disrupt or block one or more of the vital processes of the 
trypanosome. Chemotherapy, by stopping the multiplication of the 
trypanosomes, helps the immune system to overcome the infection 
by affecting some trypanosome enzyme systems, or blocking 
essential metabolic pathways. Despite the fact that chemotherapy 
is the major means of disease control, developments of new anti-
trypanosomal drugs have been more or less static over the last 
three decades,due to lack of interest by the pharmaceutical industry 
to invest into research and development of anti-trypanosomal drugs 
(Gutteridge,1985).It is well known that developing an effective 
drug for chemotherapy of protozan infections and particularly 
effective against Trypanosoma evansi is a difficult task. 
(Zhang,1999).                                                                                                                                         
  
Trypanocidal Drugs:- 
1-2-5-3-1. Isometamidium: 
 (samorin-R-, Trypamidium-R-) It is described chemically as7-
(amidinophenyldiazo-amino)-2-amino-10-ethyl-9-phenyl-phenan-
thridium. It is routinely administered intra-muscularly at doses of 
0.25-0.50 mg/kg (Kinabo, 1993) for therapeutic pruposes. 
     It is active against T. evansi infections in donkeys, horses and 
camels (Kinabo,1993). 
     The acute toxic effects of it have been reviewed in dogs, cattle, 
camels and goats (Kinabo and Bougan,1988a). 
 
1-2-5-3-2. Suramin: 
       (Germanin–R, (it is hexa-sodium3.3-Ureylene bis (8-3-
benzamido-p-toluido)-3.5Ureylene sulphonate. Suramin has been 
used primarily as a curative drug against human sleeping sickness 
and T. evansi infection in camels and equines. The standard 
therapeutic doses are7-10 mg/kg in horses and 8-12 mg/kg in 
camel given intravenously. A similar drug is also called Naganol, 
Bayer 205 or Antrypol. Knowles (1925) reported that Naganol was 
specific for the treatment of camels affected with T. evansi. The 
injection of Naganol i/v protects horses for periods ranging from1-
 2months from T. evansi infection. Samartsew, 1940 and 
Brown,1990. reported that camels with acute or chronic forms of 
surra were injected i/v with Naganol either alone or together with 
Navarsenol; the best effects followed repeated doses of Naganol at 
5 days intervals during the first fortnight after trypanosomes had 
been discovered in the blood. 
 
1-2-5-3-3. Quinapyramine: 
       (Antrycide sulphate–R). It is 4-amino-6(2-amino-6-                       
methyllqunoline-1, 1dimetho (methyle sulphate).                                                   
Infections of T. evansi have been treated effectively using 
Quinepyramine (Leach and Roberts, 1981).It was produced mainly for 
the treatment of Surra in camels and horses. 
      Three forms of this compound are used namely antrycide 
methyl-sulphate, Antrycide chloride and Antrycide pro-salt (a 
mixture of methyl-sulphate and chloride).This drug is very active 
against T. brucei and T. evansi and is well tolerated by 
bovines,ovines,caprines and camels (Soulsby,1982 and Murray et 
al,1983). They reported that Quinapyramine sulphate was the drug 
of choice for T. evansi infection in camels. It is the drug of choice 
for T. brucei in horses. It is injected subcutaneosly at the rate of 5 
mg /kg body weight. 
      Local and systemic reaction may occur and the total dose 
 should be divided in two or three parts and given at six hourly 
intervals. 
  
1-2-5-3-4.  Cymelarsan (RM110; Melcy): 
        A water-soluble trivalent arsenical agent, melarsamine 
hydrochloride (Melcy) (Trade name, cymelarsan) related to 
melarsen. 
        It is described chemically as: bis (aminoethylthio-4melamino 
phenyl arsine dihydrochloride).The name Melcy is derived from 
the chemical formula Melarsen oxide, with cysteamine as a lateral 
chain it is dispensed as a dry powder, highly soluble in water. 
          The properties of melarsamine hydrochloride (Cymelarsan) 
dissolved in aqueous solution as a   melaminophenylarsine and 
made by conjugation of one part equivalent of melarsen oxide and 
two parts equivalent to cysteamine were noted immediately after it 
was dissolved in water, the compound was found to exist as an 
equilibrium mixture containing Cymelarsan (43%), Cymelarsan 
which had lost one cysteamine moiety (cymelarsan-1;24%), 
melarsen oxide (33%), and free cysteamine in small amounts 
(<1%) as the oxidation products derived from the last two 
components (cysteamine and sodium melarsen ).On incubation at 
room temperature, the Cymelarsan content decreased steadily ,with 
an associated increase in the melarsen oxide and sodium melarsen 
 contents. After 5 days in solution at room temperature,27%of the 
arsenical agent of Cymelarsan, develops into14% Cymelarsan-
1,42% melarsen oxide,and17% sodium melaesen. Since H2O2 
production was detectable Cymelarsan in the cysteamine solution 
and the addition of small amounts of exogenous H2O2 readily 
converted the trivalent melarsen oxide to the pentavalent sodium 
melarsen.It is hypothesized that the non enzymatic conversion of 
cysteamine to cystamine produced H2O2, which then oxidized 
melarsen oxide to sodium melarsen. Similar time course 
experiments showed that melarsonyl potassium and melarsoprol 
were more stable in solution. (Fairlamb and Berger,1994). 
        The nature of Cymelarsan in solution indicates that the 
pharmacology of the compound is likely to be rather complicated. 
The existing pharmacokinetic values determined by monitoring 
total arsenic by atomic absorption and trypanocidal activity by 
bioassay are thus incomplete and need to be re examined by 
techniques that are capable of separating multiple arsenical 
compounds from the biological sample. (Reynaud and Friedheim,1986). 
       The drug was developed in the 1980s for use against Surra in 
camels (Luckins, 1999), and has been shown to be very effective 
against T. brucei., T. evansi and T. equiperdum in camels, buffalos, 
goats, pigs and in vitro.(Zweygarth et al,1992). 
      The drug was also found to be effective against diminazene 
 aceturate resistant T. evansi è )Zhang،et al،1992( . As the other 
compounds in use against this disease are either frequently 
associated with resistance problems (suramin and Quinapyramine) 
or not always sufficiently effective as isometamidium. Therefore it 
is indicated for the treatment of acute-sub acute and chronic T. 
evansi infection in camels. 
         First trials with the new arsenical, Cymelarsan in camels 
artificially infected with T. evansi have been carried out (Targer, 
Kagan etal ,1989).Treatment of the cerebral stage of African 
trypanosomosis has relied primarilly on the melaminophenyl arsin 
melarsoprol (Friedheim etal ,1949) but melarsoprol is insoluble in 
water ,with a consequence that , particularly as  an arsenical agent, 
it induced encephalopathy (Friedheim etal ,1989 ). Cymelarsan is 
administered preferably intramuscularly.  
      The trypanocidal activity of an arsenical compound 
Cymelarsan was tested in susceptible and drug resistant stocks of 
T. brucei and T. evansi Invitro and Invivo. The trypanosome 
showed different levels of susceptibility to Invitro test. (Zwegyarth 
and Kaminsky, 1990).The dosage rate originally recommended by the 
manufacture for camel Surra is 0.25 mg/kg, This dose is too low 
and that a single dose may not cure an animal with a CNS 
involvement with certainty (Zweygarth et al, 1992). 
     Cymelarsan so far appears to have been registered only for use 
 in the camel. They showed that a single dose of 0.625or1.25 mg 
/kg was fully effective and well tolerated by the camels as T.evansi 
is of eminent importance out side the African tsetse belt. (Zweygarth 
and Kaminsky, 1990). 
 
1-2-6. Chemoprophylaxis:- 
        Chemoprophylaxis or chemoprevention is the prevention of 
disease by the use of chemical drugs. 
        Logically this implies a residual effect, as prevention. It 
depends on the persistence of the drug in the system of the animal. 
A chemoprophylactic drug is also curative, but a curative drug is 
not necessarily prophylactic. There is no essential difference 
between the two categories of drugs but, drugs that can be used for 
chemoprophylaxis just persist longer. 
        Preventive drugs are administered at defined intervals, and 
care must be taken not to administer them more frequently than 
prescribed (Uilenberg,1998). Often a depot of the drug is formed at 
the site of the injection where it is retained and slowly released into 
the circulation to maintain a concentration in the blood at a level at 
which no trypanosome can exist. Other drugs are not maintained in 
the form of such a local depot,but are found loosely attached to 
blood proteins and become slowly available to act on the parasite. 
There is another way to create a drug depot, even if the drug is 
 normally only curative ,by incorporating it into a suitable support, 
after sub-cutaneous implantation, the drug will be gradually 
released, so the in adequate prophylactic(and curative) level is 
maintained in the blood and tissue fluid. 
 
1-2-7.  Drug resistance:- 
       Drug resistance may be defined as a loss of the sensitivity by a 
strain of an organism to a compound to which it had previously 
been susceptible. It implies failure of treatment or prevention, and 
if no other active drugs are available the animal has to rely on its 
immune defenses alone to combat the disease (Uilenberg, 1998). 
      Drug resistance is one of the big problems facing the control of 
trypanosomosis. Drug resistance was reported as early as 1907 
when Elrich noticed that repeated administration of the trypan red 
to trypanosome led to gradual insensitivity of the parasite to the 
preparation. This is referred to as "Drug resistance". Few and 
limited numbers of the trypanocidal drugs are available now in the 
market.This is another problem of the control trypanosomosis. 
     Drug resistance in trypanosomosis can be defined as "the ability 
of a trypanosome strain, formerly exposed to a drug, to survive, 
despite the administration and absorption of a drug given in doses 
equal to, or higher than those usually recommended" (El 
Rayah,1997). Drug resistance is not an absolute state but is correlated 
 to a particular dosage. This ranges between complete sensitivity 
and complete response of trypanosomes to trypanocides and 
ranging from a loss of effect, demonstrable only by occasional re-
appearance of the parasite in the blood, to a level of resistance at 
which the drug apparently has no effect. Drug resistance was found 
to develop, when trypanosomes were exposed to sub-curative 
doses of trypanocides (El Rayah and Elmalik, 1990) and is also related 
to the general prophylactic use of the drugs.  
     Today chemoresistance was reported against most trypanocidal 
drugs used(Williamson et al,1982).The development of resistance 
to one compound was often accompanied by cross resistance to 
another trypanocide. 
 
 
  
 CHAPTER TWO 
MATERIALS & METHODS  
2-1. Experimental animals:-                                                 
2-1-1. Rabbits:- 
      Thirty young rabbits were used. Their weight ranged 
between1.070 kg and 0.945 kg, with their average weight about 
1kg.They were kept in two separate clean pens, they were fed on 
green fodder, and were supplied with drinking water ad.libitum.      
2-1-2. Mice:- 
Twenty four mice weighing about 20-25 gm each were used. 
The mice were kept in clean plastic cages with saw dust, and were 
fed a diet composed of fresh vegetables, dried bread and oil cakes 
and were allowed free access to drinking water. 
 
2-1-3/ T.evansi isolate:- 
   A  T. evansi isolate was obtained from a naturally infected camel 
in Kordofan state. It was provided courtesy of Dr.Atif 
Elamin,Department of preventive Medicine 
The camel blood was propagated in mice. 
      Infected mouse blood was collected diluted and used for 
rabbits infection and challenge after treatment. 
 
  
2-2.  Drug:- 
The drug used in this study was:- 
Cymelarsan® manufactured by Merial(Lyon-France):each 
vial of cymelarsan contains100mg of sterile freeze dried powder 
of: (bis (aminoethylthio) - 4melaminophenylarsine 
dihydrochloride). 20 ml sterile water was added to the 100 mg 
powder to give (0.5%) concentration. A standard dose of 2.5 ml of 
the solution is given for each 50 kg of b.w. of a camel. This gives a 
dose rate of 0.5mg/kg b.w. 
 
2-3. Experimental Design:- 
     In this study two groups of animals were used to study the 
effect of cymelarsan to treat and protect against infection induced 
by T. evansi . 
2-3-1. Infection and treatment :- 
Experimental rabbits were used and were infected with T. evansi. 
T. evansi isolate was infected into mice. Parasitaemia in mice 
developed within less than a week. Mice at peak of parasitaemia 
were bled and 1.5ml diluted infected blood was inoculated 
intraperitoneally into each rabbit. 
 
 
  
 Table (1) 
Group A (Infected and treated) 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Number of Rabbits Drug %   Solution Dose 
Given in mg/ml          
       2 0,5 % 5mg/kg 
       2  0,25 % 2,5mg/kg 
       2 0,125 % 1,25mg/kg 
       2 0,0625 % 0,625mg/kg 
       2 0,0312 % 0,312mg/kg 
       2 0,0156 % 0156mg/kg 
  
Table(2) 
Group B (uninfected and treated) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of Rabbits Drug %   Solution Dose 
Given in mg/ml          
       1 0,5 % 5mg/kg 
       1  0,25 % 2,5mg/kg 
       1 0,125 % 1,25mg/kg 
       1 0,0625 % 0,625mg/kg 
       1 0,0312 % 0,312mg/kg 
       1 0,0156 % 0156mg/kg 
 Rabbits were grouped into four groups.  
A/ Infected and cymelarsan treated: consisted of 12 rabbits, they 
were given various doses cymelarsan. (Table -1). 
Control groups: 
    B/ Infected and untreated: consisted of 6 rabbits. 
    C/ Uninfected and treated: consisted of 6 rabbits. (Table- 2)  
    D/ Uninfected and untreated: consisted of 6 rabbits. (Normal).     
Cymelarsan is supplied as 100 mg powder. It was dissolved in 20 
ml sterile water before it is administered giving a 0.5% solution 
which is curative for a camel according to its weight. 
      As a rabbit is assumed to be 1kg in weight it should 
receive1/400 the weight of a camel. 
      Therefore the 0.5% solution was delivered to the rabbits in 
serial dilutions.  
      All rabbits in this experiment were treated on the same day 
after one month of trypanosomes inoculation, and appearance of 
parasitaemia,which had a chronic infection.  
       All doses of drug were inoculated intraperitoneally. 
The doses of drug were calculated for every group of rabbits as 
follow:- 
1. A dose of 1ml cymelarsan of the 0.5% solution containing 
5 mg/ml. 
2. A dose of 1ml cymelarsan of the 0.25% solution contained 
 2.5 mg/ml. That was prepared by adding 1ml sterile water to 
1ml of 0, 5% of the solution.   
3. A dose of 1ml cymelarsan of the 0.125% solution 
contained1.25 mg/ml. That was prepared by adding 1ml 
sterile water to 1ml of 0, 25% of the solution.           
4. A dose of 1ml cymelarsan of the 0.0625% solution contained 
0.625 mg/ml. That was prepared by adding 1ml sterile water to 
1ml of 0,125% of the solution.     
5. A dose of 1ml cymelarsan of the 0.0312% solution contained 
0.312 mg/ml. That was prepared by adding 1ml sterile water to 
1m of 0, 0625 % of the solution. Containing 0.625 mg.  
6/A dose of 1ml cymelarsan of the 0.0156% solution contained 
0.156 mg/ml. That was prepared by adding 1ml sterile water to 
1ml of 0, 0312% of the solution.  
 
2-3-2/Challenge and detection of relapse after treatment: 
     Each rabbit, after being treated with cymelarsan, remained            
under observation for a period of 2 months. 
     Then each treated rabbit was re-infected with T. evansi. 
    Two weeks later, samples of blood were taken from each    
rabbit. Twenty four mice were grouped into six groups, four mice 
each. Each group was sub inoculated with blood taken from the 
previously treated and reinfected rabbits. 
    
  2-4. Follow up:- 
      All inoculated rabbits were examined daily for the detection of   
parasitaemia by wet blood smear. 
      Blood samples from the reinfected rabbits were inoculated into 
mice to detect if relapse of  trypanosomes in rabbits previously 
treated occurred. Search for re-infections was made and observed 
for a period of 2 weeks for the detection of parasitaemia. 
 
 
 
 
 
 
 
 
 
 CHAPTER THREE 
Results 
 
 
This study was conducted for evaluating the efficiency of 
Cymelarsan drug on Trypanosoma evansi isolate in the rabbits 
which had a chronic infection for both treatment and protective 
activity. 
 Twelve rabbits infected with T.evansi isolate and treated with 
Cymelarsan as 5 mg/kg, 2.5 mg/kg, 1.25 mg/kg, 0.625 mg/kg, 
0.312 mg/kg and 0.156 mg/kg respectively,were all cleared of 
parasitaemia as seen in negative wet blood examination 
 
Control groups:  
-The infected and untreated group: All the rabbits of the group died 
of infection within the 10th-19th day effective from the appearance 
of the infection in their blood. 
-The uninfected and treated group: All the rabbits of the group 
remained alive and survived until the end of the experiment. 
-The uninfected and untreated group: All the rabbits of the group 
remained alive and survived till the end of the experiment. (Table 
3). 
  
 
Table (1)  Results of treatment of infected rabbits with cymelarsan: 
 
 
Rabbits group 
 
T r e a t 
Cymelarsan  treated 
M e nt 
cymelarsan 
untreated 
Total of 
rabbits 
Infected 
 
No/    Resp 
12/ 12*(100%)      
         
             
 No/  Resp 
6/ 0 ** (%) 
        18 
Uninfected 
 
 No/     Resp 
6/    6*(100%) 
 No/   Resp 
6   / 6* (100%) 
        12 
           30 
 
 
*All animal remained alive. 
** All animals died. 
 
 
 
 
 
 
  
-1.Group A (infected and treated): 
     3-1-1. Cymelarsan (5mg/kg) treated group (A): 
     Parasitological examination:- 
      Rabbits infected with T. evansi were positive on 12th day post 
inoculation and they were treated on 18th day post the first 
emergence of parasitaemia, then they were negative for the 
trypanosomes on 4th day after treatment until the end of the 
experiment. . 
  
3-1-2. Cymelarsan (2.5 mg/kg) treated group (A):- 
Parasitological examination: 
     Two rabbits showed parasitaemia in this group on 15th day and 
12th  day post inoculation in this experiment and showed clearance 
of the trypanosomes from their blood after treatment on day 4 after 
appearance of infection at dose with 2.5mg/kg.  
3-1-3. Cymelarsan (1.25 mg/kg) treated group (A):  
Parasitological examination: 
     Two rabbits were positive on7th day and 17th day respectively 
post inoculation and they were completely cured after cymelarsan 
injection at dose 1.25mg/kg on 23th day and 13th day, and they 
were free of trypanosomes after treatment on day 4 after the 
appearance of the infection. 
  
3-1-4.  Cymelarsan (0.625 mg/kg) treated group(A): 
Parasitological examination: 
       All rabbits in sub group (A) showed the trypanosomes on 7 th 
day post inoculation, and then they were treated on 23th day after 
the appearance of trypanosomes. And they were parasitological 
negative after treatment until the end of the experiment. 
 
3-1-5.  Cymelarsan (0.312 mg/kg) treated group (A): 
Parasitological examination: 
      All rabbits in sub group (A) were cured after the treatment on 
4th day with cymelarsan at dose of 0.312mg/kg on 22th day after 
appearance of infection and became cured from infection until the 
end of experiment. 
 
3-1-6./ Cymelarsan (0.156mg/kg) treated group(A):- 
Parasitological examination: 
      All rabbits in sub group (A) were cured and were not showing 
trypanosomes post treatment with cymelarsan at dose 0.156mg/kg. 
 
3-2/ Callenge of infection by mouse inoculation: 
     Twenty four mice were grouped into six groups, 4 mice each. 
Two weeks after treatment rabbits were challenge with T.evansi. 
 Blood sample were taken from the reinfected rabbit and was 
inoculated into 2 mice each. Parasitaemia was checked daily in all 
mice.  
 The last group of the rabbits failed to be protected by 0,156 mg/kg 
dose and killed prior to the end of the experiment by T.evansi. 
With regard to the prophylaxis of the drug, in this particular 
experiment, the parasitaemia appeared in two of the mice out of the 
total of twenty four mice. This indicates that at the dose used 
0,156mg/ml; Cymelarsan showed no protection and therefore it 
was not prophylactic at the prescribed dose of 0,156 mg/ml.                                   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 CHPTER  FOUR 
Discussion and Conclusions 
Chemotherapy is deemed, now days' one of the main and 
fundamental means for the control of some diseases especially 
those which have no vaccine such as trypanosomosis.                                             
Many specialists have researched into trypanocides. Several 
researches have been conducted in various types of drugs and 
animals in order to study the curative effect of the drug. Like wise, 
recently several researchers confirmed the curative effect of the 
drug, cymelarsan, against T. evansi in camels according to the a 
specified dose.                                                                             
This study has been conducted in order to know the effect of the 
different doses of cymelarasn  against a T. evansi strain in rabbits.                         
It was intended further to study if cymelarsan treated rabbits 
relapse after apparent cure and at what dose. And also if 
cymelarsan would show any prophylaxis in treated rabbits 
previously infected and treated.                                                                           
In this particular experiment, we have taken into consideration not 
knowing the T. evansi incubation period in the rabbit; therefore we 
however started the treatment immediately upon the appearance of 
the parasitaemia.                                                                          
More over, in this particular experiment, the groups of the normal 
 and untreated rabbits were considered as uninfected control and 
continued so till the end of the experiment.                                                              
Also, it is conducted to see the effect of different doses of the drug 
which would be curative to infected rabbits and which doses failed 
to cure infected rabbits. On the other hand, in the group of the 
infected-untreated rabbits, they all died prior to the end the 
experiment.                                                                     
It is observed in this group that despite of the fact that the harm 
caused by the parasite looked mild without severe symptom it led 
to the death of the infected untreated rabbits                                                           
 It is worth- to mention that the main group in the experiment is the 
group of the infected and treated rabbits. This group showed 
different grades of susceptibility for treatment by the different 
doses of cymelarsan.  Also, in the first five groups, the parasite 
disappeared, when treated within the range of (3) to (4) days 
effective from the application of the treatment.                              
Moreover the last group of the rabbits failed to be protected by 
0,156 mg/kg dose and killed prior to the end of the experiment by 
T.evansi. With regard to the prophylaxis of the drug, in this 
particular experiment, the parasitaemia appeared in two of the mice 
out of the total of twenty four mice. This indicates that at the dose 
used 0,156mg/kg,Cymelarsan showed no protection and thereforeit 
was not prophylactic at the prescribed dose of 0,156 mg/kg. 
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   اﻟﺪراﺳﺔ ﺑﺎﻟﻠﻐﺔ اﻟﻌﺮﺑﻴﺔﺧﻼﺻﺔ 
  
 ﻲ ﻓﻱ ﻋﺘﺭﺓ ﺍﻟﻤﺜﻘﺒﻴﺔ ﺍﻴﻔﺎﻨﺯﺍﻰﺍﺠﺭﻴﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﻟﺘﻘﻴﻴﻡ ﻓﻌﺎﻟﻴﺔ ﻋﻘﺎﺭ ﺴﺎﻴﻤﻠﺭﺴﺎﻥ  ﻋﻠ
  .ﺍﻻﺭﺍﻨﺏ ﻤﻥ ﻨﺎﺤﻴﺔ ﺍﻟﻌﻼﺠﻴﺔ ﻭﺍﻟﻭﻗﺎﺌﻴﺔ
ﺍﺠﺭﻴﺕ .ﺍﻻﺭﺍﻨﺏ ﻭﺍﻟﻔﺌﺭﺍﻥ :ﻥ ﻤﻥ ﺍﻟﺤﻴﻭﺍﻨﺎﺕ ﻭﻫﻤﺎ ﺍﺴﺘﺨﺩﻡ ﻓﻰ ﻫﺫﻩ ﺍﻟﺘﺠﺭﺒﺔ ﻨﻭﻋﺎ
  :ﺕ ﻤﺠﻤﻭﻋﺎﺔ ،ﻗﺴﻤﺕ ﺍﻟﻰ ﺍﺭﺒﻌﺎﹰﺭﻨﺒﺃ03 ﻓﻰ ﻋﺩﺩ ﺔﺍﻟﺘﺠﺭﺒ
، ﻜل ﺍﺜﻨﻴﻥ ﺎﹰﺭﻨﺒﺃ 21 ﻱ ﻋﻠﻰﻭﺘﻤﺠﻤﻭﻋﺔ ﻤﺼﺎﺒﻪ ﺒﻁﻔﻴل ﻭﻤﻌﺎﻟﺠﻪ ﺒﺴﺎﻴﻤﻠﺭﺴﺎﻥ ﻭﺘﺤ( 1
 ،ﻤل/ﻤﻠﺠﻡ5,2 ،ﻤل/ﻤﻠﺠﻡ5  ﻤﻥ ﺍﻟﻌﻘﺎﺭ ﻭﻫﻰ ﺔ ﻤﺨﺘﻠﻔﺔ ﺒﺠﺭﻋﺎ ﻋﻭﻟﺠﺎﻤﻨﻬﻤ
 651.0، ﻤل/ﻤﻠﺠﻡ 213.0 ﻤل/ﻤﻠﺠﻡ ﻤل/ﻤﻠﺠﻡ، 526.0، ﻤل/ﻤﻠﺠﻡ52.1
  .ﻲ ﻋﻠﻰ ﺍﻟﺘﻭﺍﻟﻤل/ﻤﻠﺠﻡ
 ﻲﺭﺍﻨﺏ ،ﻭﺘﻤﺜل ﺍﻟﻀﺎﺒﻁ ﺍﻻﻴﺠﺎﺒﺃ 6 ﻱ ﻭﺘﺤﻭﺔ ﻤﺼﺎﺒﺔ ﺒﺎﻟﻁﻔﻴل ﻭﻏﻴﺭ ﻤﻌﺎﻟﺠﺔﻤﺠﻤﻭﻋ (2
   .ﺔﻟﻠﺘﺠﺭﺒ
ﺭﺍﻨﺏ ﺤﻴﺙ ﺘﻤﺜل ﺃ 6 ﻱ ﺒﺎﻟﻌﻘﺎﺭ ﺍﻟﻤﺫﻜﻭﺭ ﺴﺎﺒﻘﺎ ﻭﺘﺤﻭﺔ ﻭﻤﻌﺎﻟﺠﺔ ﻏﻴﺭ ﻤﺼﺎﺒﺔﻤﺠﻤﻭﻋ( 3
   ﺔ ﻟﻠﺘﺠﺭﺒﻲﺍﻟﻀﺎﺒﻁ ﺍﻟﺴﻠﺒ
  .ﺭﺍﻨﺏ ﻭﺘﻤﺜل ﻀﺎﺒﻁ ﺍﻟﺘﺠﺭﺒﺔﺃ 6 ﻱ ﻭﺘﺤﻭﺔ ﻭﻏﻴﺭ ﻤﻌﺎﻟﺠﺔ ﻏﻴﺭ ﻤﺼﺎﺒﺔﻤﺠﻤﻭﻋ (4
ﻌﺕ ﻜل ﺍﻟﻤﺠﻤﻭﻋﺎﺕ ﺨﻀ .ﻲﺘﻤﺕ ﺍﻟﻌﺩﻭﻯ ﺒﺤﻘﻥ ﺍﻻﺭﺍﻨﺏ ﺒﺎﻟﻁﻔﻴل ﻓﻰ ﺍﻟﺼﻔﺎﻕ ﺍﻟﺒﻁﻨ
  : ﺒﻌﺩ ﺍﻟﻌﻼﺝ ﻭﻜﺎﻨﺕ ﺍﻟﻨﺘﺎﺌﺞ ﻜﺎﻻﺘﻰ ﺎ ﻴﻭﻤ06ﻟﻠﻔﺤﺹ ﺍﻟﻴﻭﻤﻰ ﻟﻔﺘﺭﺓ 
 ﺘﻌﺎﻟﺠﺕ ﺠﻤﻴﻊ ﺍﻻﺭﺍﻨﺏ ﺒﻤﺨﺘﻠﻑ ﺍﻟﺠﺭﻋﺎﺕ ﻤﺎ ﺒﻴﻥ  :ﺔ ﻭﺍﻟﻤﻌﺎﻟﺠﺔ ﺍﻟﻤﺼﺎﺒﺔﺍﻟﻤﺠﻤﻭﻋ (1
  .ﺍﻟﻴﻭﻡ ﺍﻟﺜﺎﻟﺙ ﻭﺍﻟﺭﺍﺒﻊ ﻤﻥ ﺍﻟﻌﻼﺝ 
 ﻨﻔﻘﺕ ﻓﻴﻤﺎ ﺒﻴﻥ ﺔﺭﺍﻨﺏ ﺍﻟﻤﺠﻤﻭﻋﺃﺠﻤﻴﻊ  :ﺔﻤﻌﺎﻟﺠﺍﻟ ﻭﻏﻴﺭ ﺔ ﺍﻟﻤﺼﺎﺒﺔﺍﻟﻤﺠﻤﻭﻋ( 2
  .ﺔ ﻤﻥ ﺍﻻﺼﺎﺒ91-01ﻭﻡﺍﻟﻴ
 ﻅﻠﺕ ﻋﻠﻰ ﻗﻴﺩ ﺍﻟﺤﻴﺎﺓ ﺔﺭﺍﻨﺏ ﺍﻟﻤﺠﻤﻭﻋﺃﺠﻤﻴﻊ : ﺔ ﻭﺍﻟﻤﻌﺎﻟﺠﺔﻤﺼﺎﺒﺍﻟ ﻏﻴﺭ ﺔﺍﻟﻤﺠﻤﻭﻋ( 3
  .ﺔﺤﺘﻰ ﻨﻬﺎﻴﺔ ﺍﻟﺘﺠﺭﺒ
 XI
    ﻅﻠﺕ ﻋﻠﻰ ﻗﻴﺩ ﺔﺭﺍﻨﺏ ﺍﻟﻤﺠﻤﻭﻋﺃﺠﻤﻴﻊ : ﺔﻤﻌﺎﻟﺠﺍﻟﻤﺼﺎﺒﻪ ﻭﻏﻴﺭ ﺍﻟﻏﻴﺭ ﺔ ﺍﻟﻤﺠﻤﻭﻋ (4
  .ﺔﺍﻟﺤﻴﺎﺓ ﺤﺘﻰ ﻨﻬﺎﻴﺔ ﺍﻟﺘﺠﺭﺒ  
  .ﺔ ﻫﻰ ﺍﻟﻔﺌﺭﺍﻥ ﺍﻟﻤﻌﻤﻠﻴﺔﻰ ﺍﻟﺘﺠﺭﺒ ﻤﻥ ﺍﻟﺤﻴﻭﺍﻨﺎﺕ ﺍﻟﺘﻰ ﺍﺴﺘﺨﺩﻤﺕ ﻓﻲﺍﻟﻨﻭﻉ ﺍﻟﺜﺎﻨ
  . ﻓﺌﺭﺍﻥ4 ﻱ ﺘﺤﻭﺔﻜل ﻤﺠﻤﻭﻋ  ﺴﺕ ﻤﺠﻤﻭﻋﺎﺕ،ﻰﻟﺇﺭ ،ﻗﺴﻤﺕ ﺄ ﻓ 42ﺘﻡ ﺍﺨﺘﺒﺎﺭ 
 1 ﺔﺨﺫﺕ ﻋﻴﻨﺔ ﺩﻡ ﻤﻥ ﺍﻻﺭﺍﻨﺏ ﻓﻰ ﺍﻟﻤﺠﻤﻭﻋﺃﺒﻌﺩ ﺍﺴﺒﻭﻋﻴﻥ ﻤﻥ ﺍﻟﻌﻼﺝ ﻭﺍﺨﺘﻔﺎﺀ ﺍﻟﻁﻔﻴل 
 ﻋﺩﻡ ﻅﻬﻭﺭ ﺍﻟﻁﻔﻴل ﻓﻰ ﻤﺠﺭﻯ ﺍﻟﺩﻡ ﻓﻴﻤﺎ ﻋﺩﺍ ﺍﺜﻨﻴﻥ ﺔﻭﻜﺎﻨﺕ ﺍﻟﻨﺘﻴﺠ.ﻭﺤﻘﻨﺕ ﻓﻰ ﺍﻟﻔﺌﺭﺍﻥ 
   . ﻭﺍﻟﻠﺫﺍﻥ ﺘﻠﻘﻴﺎ ﺩﻤﺎﹰ ﻤﻥ ﺍﻻﺭﺍﻨﺏ ﺍﻟﺘﻰ ﺘﻠﻘﺕ ﺍﻗل ﺠﺭﻋﺔ ﻤﻥ ﺍﻟﺩﻭﺍﺀﻤﻥ ﺍﻟﻔﺌﺭﺍﻥ
 ﺒﺎﻟﺠﺭﻋﺎﺕ  ﻓﻰ ﺍﻻﺭﺍﻨﺏ ﻤﺩﻯ ﻋﻼﺠﻴﺔ ﻭﻭﻗﺎﺌﻴﺔ ﻋﻘﺎﺭ ﺍﻟﺴﺎﻴﻤﺭﺴﺎﻥﺔﺍﻅﻬﺭﺕ ﺍﻟﺘﺠﺭﺒ* 
ﻤل ﺍﻟﺘﻰ ﺍﻅﻬﺭﺕ ﻋﺩﻡ /ﻤﻠﺠﻡ 651.0 ﺔﻓﻴﻤﺎ ﻋﺩﺍ ﺍﻟﺠﺭﻋ  ﺍﻨﻔﺎ،ﺓ ﻭﺍﻟﻤﺫﻜﻭﺭﺔﺍﻟﻤﺴﺘﺨﺩﻤ
  . ﺔﺍﻟﻭﻗﺎﻴﻰ ﻋﻠﻤﻘﺩﺭﺘﻬﺎ
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